PMID- 15325099
OWN - NLM
STAT- MEDLINE
DCOM- 20040930
LR  - 20071115
IS  - 0165-4608 (Print)
IS  - 0165-4608 (Linking)
VI  - 153
IP  - 1
DP  - 2004 Aug
TI  - Combined cytogenetic testing and fluorescence in situ hybridization analysis in 
      the study of chronic lymphocytic leukemia and multiple myeloma.
PG  - 73-6
AB  - We investigated the usefulness of fluorescence in situ hybridization (FISH) 
      panels when testing for chromosomal aberrations of known prognostic significance 
      in chronic lymphocytic leukemia (CLL) and multiple myeloma (MM). Our CLL panel 
      included probes for 11q, 12 centromere, 13q, 14, and 17p. Karyotype and FISH were 
      abnormal in 13 of 60 (21.6%) cases, two (3.3%) abnormal by karyotype alone, and 
      25 (41.6%) by FISH alone. Karyotype and FISH were normal in 16 (27%) patients, 
      and 4 samples were unsuitable for karyotype analysis. One patient had an 
      abnormality not included in the panel (20q deletion). FISH was abnormal in 19 
      cases (31.6%) with a normal karyotype and in 6 cases with no analyzable 
      metaphases. Thirteen CLL cases with abnormal karyotypes were either confirmed or 
      clarified by FISH. The MM panel probes were 11q, 13q, 17p, and t(11;14). 
      Karyotype and FISH were abnormal in 18 of 139 (13%) MM cases. Twenty patients 
      (14.4%) had a normal karyotype and abnormal FISH. Two samples not suitable for 
      metaphase analysis were abnormal by interphase FISH. Karyotype and FISH were 
      normal in 94 (68%) patients. Five patients (3.6%) had chromosomal abnormalities 
      not included in the panel. Compared to karyotyping alone, the FISH panels 
      improved the detection rate of recurrent chromosomal aberrations in CLL from 
      22-63% and in MM from 15-29%.
FAU - Wiktor, Anne
AU  - Wiktor A
AD  - Department of Medical Genetics, Henry Ford Health System, 2799 W. Grand 
      Boulevard, Clara Ford Pavilion 461, Detroit, MI 48202, USA.
FAU - Van Dyke, Daniel L
AU  - Van Dyke DL
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Cancer Genet Cytogenet
JT  - Cancer genetics and cytogenetics
JID - 7909240
SB  - IM
MH  - Aged
MH  - Aneuploidy
MH  - Bone Marrow/pathology
MH  - *Chromosome Aberrations
MH  - Female
MH  - Humans
MH  - *In Situ Hybridization, Fluorescence
MH  - Karyotyping
MH  - Leukemia, Lymphocytic, Chronic, B-Cell/blood/*genetics/pathology
MH  - Male
MH  - Middle Aged
MH  - Multiple Myeloma/*genetics/pathology
EDAT- 2004/08/25 05:00
MHDA- 2004/10/01 05:00
CRDT- 2004/08/25 05:00
PHST- 2003/12/19 00:00 [received]
PHST- 2004/03/10 00:00 [accepted]
PHST- 2004/08/25 05:00 [pubmed]
PHST- 2004/10/01 05:00 [medline]
PHST- 2004/08/25 05:00 [entrez]
AID - S0165460804001190 [pii]
AID - 10.1016/j.cancergencyto.2004.03.006 [doi]
PST - ppublish
SO  - Cancer Genet Cytogenet. 2004 Aug;153(1):73-6. doi: 
      10.1016/j.cancergencyto.2004.03.006.